Have you used an SGLT2 inhibitor (one of the "-flozin" drugs) to treat your horse? If so, the Equine 
(c) Brian Sedgbeer Dreamstime.com
Cushing's and Insulin Resistance Group (ECIR) invites you to contribute to an important research initiative.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as ertugliflozin and canagliflozin, are increasingly used to manage equine metabolic syndrome (EMS), particularly in horses with laminitis that has not responded to dietary changes. These drugs have shown potential benefits, including reducing serum insulin levels, aiding weight loss, and improving laminitis associated with hyperinsulinemia.
However, concerns have arisen about possible side effects, such as elevated serum triglycerides and liver enzyme levels, lethargy, and increased drinking and urination.
Dr. Kellon of the ECIR Group has created a survey to investigate factors that may influence the outcomes of SGLT2 inhibitor use in horses. This includes individual horse characteristics, comorbidities, and dietary factors that may contribute to or mitigate adverse effects.
If you are an owner, veterinarian, or caretaker of a horse receiving one of these drugs—such as canagliflozin, ertugliflozin, or dapagliflozin—you are encouraged to participate in the survey. Your insights will help enhance understanding and improve the management of metabolic disorders in horses and ponies.
The survey can be found here www.surveymonkey.com/r/YM5JD9G
See also:
Eleanor M. Kellon, V.M.D. (Equine Nutritional Solutions)
Equine Cushing's and Insulin Resistance Group Inc.
